Insulet (NASDAQ:PODD) Director Timothy Stonesifer Buys 2,790 Shares

Insulet Corporation (NASDAQ:PODD) Director Timothy Stonesifer acquired 2,790 shares of the firm’s stock in a transaction dated Wednesday, June 3rd. The shares were purchased at an average cost of $143.51 per share, with a total value of $400,392.90. Following the completion of the transaction, the director owned 9,041 shares in the company, valued at approximately $1,297,473.91. The trade was a 44.63% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Insulet Price Performance

Insulet stock opened at $146.41 on Friday. The stock has a market cap of $10.14 billion, a P/E ratio of 34.05, a price-to-earnings-growth ratio of 1.13 and a beta of 1.13. The company has a fifty day simple moving average of $176.99 and a 200-day simple moving average of $239.50. Insulet Corporation has a 12-month low of $140.63 and a 12-month high of $354.88. The company has a current ratio of 2.49, a quick ratio of 1.81 and a debt-to-equity ratio of 0.71.

Insulet (NASDAQ:PODD) last released its quarterly earnings data on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.19 by $0.23. The business had revenue of $761.70 million during the quarter, compared to analysts’ expectations of $729.89 million. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The company’s revenue for the quarter was up 33.9% on a year-over-year basis. During the same period in the previous year, the company earned $1.02 EPS. Insulet has set its FY 2026 guidance at 6.210- EPS. Equities analysts expect that Insulet Corporation will post 6.44 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of PODD. Glenmede Investment Management LP raised its holdings in shares of Insulet by 1.6% in the third quarter. Glenmede Investment Management LP now owns 2,292 shares of the medical instruments supplier’s stock valued at $708,000 after purchasing an additional 35 shares during the last quarter. Curi Capital LLC raised its holdings in shares of Insulet by 0.8% in the second quarter. Curi Capital LLC now owns 4,346 shares of the medical instruments supplier’s stock valued at $1,365,000 after purchasing an additional 36 shares during the last quarter. WINTON GROUP Ltd raised its holdings in shares of Insulet by 0.9% in the third quarter. WINTON GROUP Ltd now owns 4,086 shares of the medical instruments supplier’s stock valued at $1,261,000 after purchasing an additional 37 shares during the last quarter. Camarda Financial Advisors LLC raised its holdings in shares of Insulet by 0.5% in the second quarter. Camarda Financial Advisors LLC now owns 7,332 shares of the medical instruments supplier’s stock valued at $2,304,000 after purchasing an additional 40 shares during the last quarter. Finally, Great Lakes Advisors LLC raised its holdings in shares of Insulet by 1.5% in the fourth quarter. Great Lakes Advisors LLC now owns 2,784 shares of the medical instruments supplier’s stock valued at $791,000 after purchasing an additional 40 shares during the last quarter.

Analyst Upgrades and Downgrades

PODD has been the topic of several research analyst reports. Truist Financial cut their price target on shares of Insulet from $315.00 to $250.00 and set a “buy” rating on the stock in a research note on Thursday, May 7th. Citigroup cut their price target on shares of Insulet from $175.00 to $165.00 and set a “neutral” rating on the stock in a research note on Thursday, May 28th. Oppenheimer cut their price target on shares of Insulet from $300.00 to $210.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. Bank of America cut their price target on shares of Insulet from $288.00 to $208.00 and set a “buy” rating on the stock in a research note on Monday, May 18th. Finally, Benchmark reiterated a “buy” rating on shares of Insulet in a research note on Wednesday, May 27th. Twenty-one research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $252.04.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.